Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2073)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 24, 2024 (publication date) through Apr 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol 2024; 15(7): 859-866 [PMID: 39071470 DOI: 10.5306/wjco.v15.i7.859] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm |
| Number | Citing Articles |
| 1 |
Robert Connor Chick, Timothy M. Pawlik. Updates in Immunotherapy for Pancreatic Cancer. Journal of Clinical Medicine 2024; 13(21): 6419 doi: 10.3390/jcm13216419
|
| 2 |
Yuan-Yuan Wu, Hua Shao. Research progress of sintilimab in the treatment of cancer (Review). Oncology Letters 2025; 29(5): 1 doi: 10.3892/ol.2025.14986
|
| 3 |
Antonio Pontoriero, Gianluca Ferini. Editorial: Recent developments in pancreatic cancer radiotherapy, vol II. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1541855
|
| 4 |
Shiyun Cui, Lei Fan, Xinnan Sun, Yucheng Cai, Ting Wang, Ping Li, Rong Wang, Lianke Liu. Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma. Oncology Letters 2025; 29(5): 1 doi: 10.3892/ol.2025.14990
|